Roche’s diagnostic sales high thanks to Delta variant

SWITZERLAND – The delta variant’s high demand for COVID-19 diagnostics has resulted in rocketing sales at Roche’s diagnostics division, allowing the company to raise its sales forecast for the year. Diagnostics sales increased 39% year on year to CHF 13.3 billion (US$14.4 billion), with the strong performance of the company’s COVID-19 test kits backed up by a recovery in other products as health services begin to recover from the impact of the pandemic last year. In the first half, the company predicted that diagnostic sales would begin to decline in…

Read More

Biogen signs collaborative agreement with Innocare to use orelabrutinib as potential therapy for multiple sclerosis

WORLD – Biogen and Innocare, a biopharmaceutical company rooted in China, have signed a license and a collaboration agreement for the use of Orelabrutinib that could potentially be used to treat multiple sclerosis. Under the terms of the agreement, Biogen will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China, while Innocare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China. InnoCare will receive a US$125M upfront payment and is eligible to…

Read More